Skip to main content
Top
Published in: International Urology and Nephrology 10/2019

01-10-2019 | Nephrectomy | Urology - Original Paper

Emphysematous pyelonephritis treatment strategies in correlation to the CT classification: have the current experience and prognosis changed?

Authors: Mohamed Mohamed Elawdy, Yasser Osman, Rasha T. Abouelkheir, Samer El-Halwagy, Bassam Awad, Mohsen El-Mekresh

Published in: International Urology and Nephrology | Issue 10/2019

Login to get access

Abstract

Purpose

In view of the differences in early and late management experiences based on Huang and Tseng CT classification of emphysematous pyelonephritis (EP), our study included 34 patients aimed to re-correlate the current management plans with CT classification.

Methods

A retrospective review from January 2009 to December 2018, in patients with primary or final diagnosis of EP. Data included; patients’ demographics, routine laboratory and imaging work-up. CT was performed for all, and images were classified based on Huang and Tseng classification. The CT classification was correlated to the laboratory parameters and the final treatment plans. Data were collected and analyzed using SPSS®.

Results

Complete data for 34 patients were analyzed. The majority (70%) had positive urine culture, and Carbapenems and Ureidopenicillin were the most commonly used antibiotics. Based on CT classification, 75% (26/34) of the patients were in class I and II, 6 cases with class IIIa, and only two with class IIIb, with no cases of class IV. All patients in class I and II responded well to the medical therapy, and eight required PCN/DJ. Four required nephrectomy in class III, with zero mortality.

Conclusion

Patients in class I and II comprise the majority of EP patients, and respond well to medical treatment with excellent outcome. Insertion of PCN and DJ are not required routinely, but with urinary obstruction requiring drainage, and a few cases who required nephrectomy–all with class III. Our data show improvement in the overall survival in patients for EP.
Literature
1.
go back to reference Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II (2007) Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol 178(3 Pt 1):880–885 (quiz 1129 ) CrossRef Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II (2007) Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol 178(3 Pt 1):880–885 (quiz 1129 ) CrossRef
2.
go back to reference Huang JJ, Tseng CC (2000) Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 160(6):797–805CrossRef Huang JJ, Tseng CC (2000) Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 160(6):797–805CrossRef
3.
go back to reference Saadi A, Ayed H, Bouzouita A, Cherif M, Kerkeni W, Selmi S et al (2016) Results of conservative management of emphysematous pyelonephritis. Nephrol Ther 12(7):508–515 (Resultats du traitement conservateur de la pyelonephrite emphysemateuse. fre) CrossRef Saadi A, Ayed H, Bouzouita A, Cherif M, Kerkeni W, Selmi S et al (2016) Results of conservative management of emphysematous pyelonephritis. Nephrol Ther 12(7):508–515 (Resultats du traitement conservateur de la pyelonephrite emphysemateuse. fre) CrossRef
4.
go back to reference Eswarappa M, Suryadevara S, John MM, Kumar M, Reddy SB, Suhail M (2018) Emphysematous pyelonephritis case series from south India. Kidney Int Rep 3(4):950–955CrossRef Eswarappa M, Suryadevara S, John MM, Kumar M, Reddy SB, Suhail M (2018) Emphysematous pyelonephritis case series from south India. Kidney Int Rep 3(4):950–955CrossRef
5.
go back to reference Sharma PK, Sharma R, Vijay MK, Tiwari P, Goel A, Kundu AK (2013) Emphysematous pyelonephritis: our experience with conservative management in 14 cases. Urol Ann 5(3):157–162CrossRef Sharma PK, Sharma R, Vijay MK, Tiwari P, Goel A, Kundu AK (2013) Emphysematous pyelonephritis: our experience with conservative management in 14 cases. Urol Ann 5(3):157–162CrossRef
6.
go back to reference Kuchay MS, Laway BA, Bhat MA, Mir SA (2014) Medical therapy alone can be sufficient for bilateral emphysematous pyelonephritis: report of a new case and review of previous experiences. Int Urol Nephrol 46(1):223–227CrossRef Kuchay MS, Laway BA, Bhat MA, Mir SA (2014) Medical therapy alone can be sufficient for bilateral emphysematous pyelonephritis: report of a new case and review of previous experiences. Int Urol Nephrol 46(1):223–227CrossRef
7.
go back to reference Shokeir AA, El-Azab M, Mohsen T, El-Diasty T (1997) Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology 49(3):343–346CrossRef Shokeir AA, El-Azab M, Mohsen T, El-Diasty T (1997) Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology 49(3):343–346CrossRef
8.
go back to reference Misgar RA, Mubarik I, Wani AI, Bashir MI, Ramzan M, Laway BA (2016) Emphysematous pyelonephritis: a 10-year experience with 26 cases. Indian J Endocrinol Metab 20(4):475–480CrossRef Misgar RA, Mubarik I, Wani AI, Bashir MI, Ramzan M, Laway BA (2016) Emphysematous pyelonephritis: a 10-year experience with 26 cases. Indian J Endocrinol Metab 20(4):475–480CrossRef
9.
go back to reference Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D (2009) Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol 41(4):959–966CrossRef Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D (2009) Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol 41(4):959–966CrossRef
10.
go back to reference Das D, Pal DK (2016) Double J stenting: a rewarding option in the management of emphysematous pyelonephritis. Urol Ann 8(3):261–264CrossRef Das D, Pal DK (2016) Double J stenting: a rewarding option in the management of emphysematous pyelonephritis. Urol Ann 8(3):261–264CrossRef
11.
go back to reference Sokhal AK, Kumar M, Purkait B, Jhanwar A, Singh K, Bansal A et al (2017) Emphysematous pyelonephritis: changing trend of clinical spectrum, pathogenesis, management and outcome. Turk J Urol 43(2):202–209CrossRef Sokhal AK, Kumar M, Purkait B, Jhanwar A, Singh K, Bansal A et al (2017) Emphysematous pyelonephritis: changing trend of clinical spectrum, pathogenesis, management and outcome. Turk J Urol 43(2):202–209CrossRef
12.
go back to reference Pontin AR, Barnes RD (2009) Current management of emphysematous pyelonephritis. Nat Rev Urol 6(5):272–279CrossRef Pontin AR, Barnes RD (2009) Current management of emphysematous pyelonephritis. Nat Rev Urol 6(5):272–279CrossRef
13.
go back to reference Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P et al (2014) Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol 12(2):106–115CrossRef Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P et al (2014) Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol 12(2):106–115CrossRef
Metadata
Title
Emphysematous pyelonephritis treatment strategies in correlation to the CT classification: have the current experience and prognosis changed?
Authors
Mohamed Mohamed Elawdy
Yasser Osman
Rasha T. Abouelkheir
Samer El-Halwagy
Bassam Awad
Mohsen El-Mekresh
Publication date
01-10-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 10/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02220-3

Other articles of this Issue 10/2019

International Urology and Nephrology 10/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.